news
Targeted drug found to combat certain pancreatic tumours
Researchers have found that the CDK inhibitor AT7519 could be used to treat pancreatic cancer patients whose tumours are addicted to mutant KRAS.
List view / Grid view
Drug Development
article
Drug Target Review – Issue 2 2021
This issue includes articles on novel AAV vectors to deliver ocular gene therapy, how phenotypic models of disease are being used in covalent fragment screening and the challenges and opportunities presented by automation in the life sciences. Also in this issue are features on stem cells, antibodies and hit-to-lead.
news
Potential ovarian cancer treatment proves effective in pre-clinical studies
A new radiopharmaceutical compound has shown success at treating ovarian cancer in mice and in vitro studies.
news
Senolytic drugs reduce COVID-19 symptoms in mice, study shows
In pre-clinical studies, senolytic drugs were found to reduce inflammation and death from COVID-19 in older mice.
news
Study shows how novel drug screen can personalise cancer therapy
A screening method called dynamic BH3 profiling can identify potentially effective combinations of existing drugs for personalised cancer therapy, research has shown.
news
Molecules from resin combat epileptic seizures in pre-clinical studies
Drug molecules from pine and spruce trees can affect certain ion channels and had antiseizure effects in pre-clinical studies.
news
TEMPOL drug shows promise as antiviral treatment for COVID-19
The experimental drug TEMPOL has demonstrated antiviral activity against COVID-19 in a pre-clinical study in cell cultures.
news
Broadly neutralising antibodies could form basis of influenza vaccine
Antibodies produced by B cells against the H1N1 influenza virus can also neutralise other strains, which could be used to developed vaccines.
webinar
Automating functional cell-based bioassays: assay reproducibility and performance for potency testing programmes
28 May 2021 | By Eurofins DiscoverX* and Tecan
In this on-demand webinar, we discuss how Eurofins DiscoverX’s off-the-shelf, MOA-based functional, cellular assays address these challenges, enabling drug discovery programmes up to late-stage development and market release.
news
Inhaled nanobodies effective against SARS-CoV-2 in hamsters
Researchers have shown that inhalable nanobodies at ultra-low doses can effectively neutralise SARS-CoV-2 in hamsters.
news
Analogue of psychedelic ibogaine reverses effects of stress in mice
Tabernanthalog (TBG), similar to the psychedelic drug ibogaine, corrected stress-induced behavioural deficits in mice.
news
Researchers synthesise potential anticancer compounds
Scientists have developed six new derivatives of 4-chloro-1,2-dithiol-3-thione, which have all demonstrated anticancer effects in pre-clinical studies.
webinar
Advantages of including untargeted and targeted metabolomics into drug development and clinical trials
25 May 2021 | By Metabolon
Discover how metabolomics can support your biomarker strategy in drug development and clinical trials in this on-demand webinar.
news
Potential SARS-CoV-2 antiviral to be tested in human lung cells
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.
news
High-throughput screening assay developed to discover antimalarials
A new assay has been developed to screen for small molecule inhibitors of the Rh5 protein, which is essential for malaria parasite survival.
